Bio Rad Laboratories Inc (BIO) Actualités

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad leads investment to support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations...

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its...

Valerio Therapeutics Annonce ses Résultats Financiers du Premier Semestre 2024 et Fait le point sur ses Activités

Acquisition d'Emglev Therapeutics pour se concentrer sur la découverte d'anticorps à domaine unique (sdAbs) L’essai VIO-01 est actuellement en...

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap...

Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad Reports Second-Quarter 2024 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced...

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its...

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities